A case of primary aldosteronism with a negative aldosterone-to-renin ratio
Tóm tắt
Primary aldosteronism (PA), as a cause of secondary hypertension, can cause more serious cardiovascular damage than essential hypertension. The aldosterone-to-renin ratio (ARR) is recommended as the most reliable screening method for PA, but ARR screening is often influenced by many factors. PA cannot be easily excluded when negative ARR. We report the case of a 45-year-old Chinese man with resistant hypertension. Three years ago, he underwent a comprehensive screening for secondary hypertension, including the ARR, and the result was negative. After that, the patient's blood pressure was still poorly controlled with four kinds of antihypertensive drugs, the target organ damage of hypertension progressed, and hypokalaemia was difficult to correct. When the patient was hospitalized again for comprehensive examination, we found that aldosterone levels had significantly increased, although the ARR was negative. An inhibitory test with saline was further carried out, and the results suggested that aldosterone was not inhibited; therefore, PA was diagnosed. We performed a unilateral adenoma resection for this patient, and spironolactone was continued to control blood pressure. After the operation, blood pressure is well controlled, and hypokalaemia is corrected. When the ARR is negative, PA cannot be easily excluded. Comprehensive analysis and diagnosis should be based on the medication and clinical conditions of patients.
Tài liệu tham khảo
Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45(1):3–17.
Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331–6.
Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826–33.
Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to renin ratio as screening tool in primary aldosteronism. Exp Clin Endocrinol Diabetes. 2019;127(2–03):84–92.
Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981;141(12):1589–93.
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916.
Mulatero P, Sechi LA, Williams TA, Lenders JWM, Reincke M, Satoh F, et al. Genetics, prevalence, screeningand confirmation of primary aldosteronism: a position statement and consensusof the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020;38(10):1919–28.
Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63(1):151–60.
St-Jean M, Bourdeau I, Martin M, Lacroix A. Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism. J Clin Endocrinol Metab. 2021;106(1):e45–60.
El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Front Endocrinol (Lausanne). 2016;7:72.
Markou A, Sertedaki A, Kaltsas G, Androulakis II, Marakaki C, Pappa T, et al. Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab. 2015;100(8):2857–64.
Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173(1):10–20.
Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892–6.
Oelkers W, Diederich S, Bahr V. Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage. J Clin Endocrinol Metab. 2000;85(9):3266–70.
Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol. 2007;2(4):722–31.
Zorzi F, Olivieri O, Brazzarola P, Pizzolo F. A late diagnosis of primary aldosteronism. High Blood Press Cardiovasc Prev. 2017;24(3):347–9.
Morimoto R, Satani N, Iwakura Y, Ono Y, Kudo M, Nezu M, et al. A case of bilateral aldosterone-producing adenomas differentiated by segmental adrenal venous sampling for bilateral adrenal sparing surgery. J Hum Hypertens. 2016;30(6):379–85.
Watanabe N, Tsunoda K, Sasano H, Omata K, Imai Y, Ito S, et al. Bilateral aldosterone -producing adenomas in two patients diagnosed by immunohistochemical analysis of steroidogenic enzymes. Tohoku J Exp Med. 1996;179(2):123–9.
Chung SD, Huang KH, Yu HJ, Wu KD, Chueh SC. Diagnosis of bilateral ldosterone-producing adenomas. Kidney Int. 2007;72(2):228.
Wu VC, Chueh SC, Chang HW, Lin WC, Liu KL, Li HY, et al. Bilateral aldosterone-producing adenomas: differentiation from bilateral adrenal hyperplasia. QJM. 2008;101(1):13–22.
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51–9.
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72(3):658–66.
Miyake Y, Tanaka K, Nishikawa T, Naruse M, Takayanagi R, Sasano H, et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocr J. 2014;61(1):35–40.
Vaidya A, Mulatero P, Baudrand R, Adler GK. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev. 2018;39(6):1057–88.